Vascular involvement in systemic sclerosis (scleroderma)

Systemic sclerosis (SSc) is an acquired multiorgan connective tissue disease with variable mortality and morbidity dictated by clinical subset type. The etiology of the basic disease and pathogenesis of the systemic autoimmunity, fibrosis, and fibroproliferative vasculopathy are unknown and debated. In this review, the spectrum of vascular abnormalities and the options currently available to treat the vascular manifestations of SSc are discussed. Also discussed is how the hallmark pathologies (ie, how autoimmunity, vasculopathy, and fibrosis of the disease) might be effected and interconnected with modulatory input from lysophospholipids, sphingosine 1-phosphate, and lysophosphatidic acid.

• Publication year

  2011

• Venue

  Journal of Inflammation Research

• Publication date

  2011-07-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.2147/JIR.S18145PMID 22096374PMCID 3218751
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Drug Treatment of Scleroderma

  2012cited by this paper
• Diagnosis and Management of Systemic Sclerosis

  2012cited by this paper
• Epidemiology and classification of scleroderma

  2011influential reference
• Antioxidant effect of Iloprost: current knowledge and therapeutic implications for systemic sclerosis.

  2011cited by this paper
• HLA-B35 Upregulates Endothelin-1 and Downregulates Endothelial Nitric Oxide Synthase via Endoplasmic Reticulum Stress Response in Endothelial Cells

  2010cited by this paper
• Enhanced fibrillin-2 expression is a general feature of wound healing and sclerosis: potential alteration of cell attachment and storage of TGF-β

  2010cited by this paper
• Inhibition of bleomycin-induced pulmonary fibrosis through pre-treatment with collagen type V.

  2010cited by this paper
• B lymphocytes: Shedding new light on the pathogenesis of systemic sclerosis

  2010cited by this paper
• The genetics of systemic sclerosis.

  2010cited by this paper
• Cellular and molecular aspects of vascular dysfunction in systemic sclerosis

  2010cited by this paper
• Targeted therapy for systemic sclerosis: how close are we?

  2010cited by this paper
• Pharmacotherapy of systemic sclerosis

  2010influential reference
• Stimulation with type I collagen induces changes in gene expression in peripheral blood mononuclear cells from patients with diffuse cutaneous systemic sclerosis (scleroderma)

  2010cited by this paper
• Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

  2010cited by this paper
• Future treatments in systemic sclerosis

  2010cited by this paper
• The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis.

  2010cited by this paper
• Mutations in Fibrillin-1 Cause Congenital Scleroderma: Stiff Skin Syndrome

  2010cited by this paper
• A higher degree of criticism about the effectiveness of bosentan for digital ulcers in scleroderma patients, as for interstitial disease, is also necessary: comment on the article by Seibold et al.

  2010cited by this paper
• A role for lysophosphatidic acid and sphingosine 1-phosphate in the pathogenesis of systemic sclerosis.

  2010influential reference
• Poly(I:C) drives type I IFN- and TGFβ-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis.

  2010cited by this paper
• Is pulmonary arterial hypertension really a late complication of systemic sclerosis?

  2010cited by this paper
• Lysophosphatidic acid-activated Cl- current activity in human systemic sclerosis skin fibroblasts.

  2010cited by this paper
• MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial.

  2009cited by this paper
• Increased Frequency and Compromised Function of T Regulatory Cells in Systemic Sclerosis (SSc) Is Related to a Diminished CD69 and TGFβ Expression

  2009cited by this paper
• The Pronounced Th17 Profile in Systemic Sclerosis (SSc) Together with Intracellular Expression of TGFβ and IFNγ Distinguishes SSc Phenotypes

  2009cited by this paper
• Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis

  2009cited by this paper
• Sphingosine-1-phosphate and modulation of vascular tone.

  2009cited by this paper
• S1P1 receptor overrides regulatory T cell-mediated immune suppression through Akt-mTOR

  2009cited by this paper
• Tadalafil Therapy for Pulmonary Arterial Hypertension

  2009cited by this paper
• What are the new milestones in the pathogenesis of systemic sclerosis?

  2009cited by this paper
• Bosentan

  2009cited by this paper
• Scleroderma (systemic sclerosis) among Nigerians

  2009cited by this paper
• Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)

  2009cited by this paper
• Neuronal regulators and vascular dysfunction in Raynaud's phenomenon and systemic sclerosis.

  2009cited by this paper
• Prostacyclin analogue iloprost influences endothelial cell-associated soluble adhesion molecules and growth factors in patients with systemic sclerosis: a time course study of serum concentrations.

  2009cited by this paper
• Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation.

  2009cited by this paper
• The treatment with N-acetylcysteine of Raynaud’s phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients

  2009cited by this paper
• EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)

  2009influential reference
• Elevated Serum Levels of Arachidonoyl-lysophosphatidic Acid and Sphingosine 1-Phosphate in Systemic Sclerosis

  2009cited by this paper
• Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication

  2009cited by this paper
• Lysophosphatidic acid-induced arterial wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR.

  2009cited by this paper
• Successful Treatment of Systemic-Sclerosis-Related Digital Ulcers with a Selective Endothelin Type A Receptor Antagonist (Sitaxentan)

  2009cited by this paper
• Regulator of G protein signaling 5: a new player in vascular remodeling.

  2009cited by this paper
• Is pulmonary arterial hypertension really a late complication of systemic sclerosis?

  2009cited by this paper
• Scleroderma.

  2009cited by this paper
• Abnormalities in the Regulators of Angiogenesis in Patients with Scleroderma

  2009cited by this paper
• Innate immunity and inflammation in systemic sclerosis

  2009cited by this paper
• Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study

  2009cited by this paper
• Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension.

  2008cited by this paper
• Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.

  2008cited by this paper
• EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells

  2008cited by this paper
• Lysophosphatidic acid and renal fibrosis.

  2008cited by this paper
• Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis.

  2008cited by this paper
• Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype?

  2008cited by this paper
• Unusual presentation of progressive systemic sclerosis.

  2008cited by this paper
• Allergen induces the migration of platelets to lung tissue in allergic asthma.

  2008cited by this paper
• Alteration in protein kinase B (AKT) activity in platelets from patients with systemic sclerosis.

  2008cited by this paper
• Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis.

  2008influential reference
• Transcriptional Regulation of Bim by FOXO3a and Akt Mediates Scleroderma Serum–Induced Apoptosis in Endothelial Progenitor Cells

  2008cited by this paper
• Vascular disease in scleroderma: mechanisms of vascular injury.

  2008influential reference
• A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.

  2008cited by this paper
• Sphingosine-1-phosphate (S1P) is a novel fibrotic mediator in the eye.

  2008cited by this paper
• Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis.

  2008cited by this paper
• The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak

  2008cited by this paper
• Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis.

  2008influential reference
• Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.

  2008cited by this paper
• Sphingosine-1-phosphate and sphingosine kinase are critical for transforming growth factor-beta-stimulated collagen production by cardiac fibroblasts.

  2008cited by this paper
• Digital ulcers and outcomes assessment in scleroderma.

  2008cited by this paper
• Molecular Subsets in the Gene Expression Signatures of Scleroderma Skin

  2008cited by this paper
• Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo.

  2008cited by this paper
• Raynaud's phenomenon: pathogenesis and management.

  2008influential reference
• The pathology of scleroderma vascular disease.

  2008cited by this paper
• Circulating endothelial progenitor cells in systemic sclerosis: association with disease severity

  2008cited by this paper
• Genetic factors in systemic sclerosis

  2007cited by this paper
• Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis

  2007cited by this paper
• Autopsy case of systemic sclerosis with severe pulmonary hypertension

  2007cited by this paper
• Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases.

  2007cited by this paper
• Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis.

  2007cited by this paper
• The diagnosis and treatment of Raynaud's phenomenon: a practical approach.

  2007influential reference
• Cutting Edge: Alternative Signaling of Th17 Cell Development by Sphingosine 1-Phosphate1

  2007cited by this paper
• Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis.

  2007cited by this paper
• Sildenafil for pulmonary arterial hypertension associated with connective tissue disease.

  2007influential reference
• Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril.

  2007cited by this paper
• Platelet contributions to the pathogenesis of systemic sclerosis

  2007cited by this paper
• Scleroderma renal crisis: patient characteristics and long-term outcomes.

  2007cited by this paper
• Antiangiogenic plasma activity in patients with systemic sclerosis.

  2007cited by this paper
• LPA1 receptor activation promotes renal interstitial fibrosis.

  2007cited by this paper
• The burden of pulmonary hypertension

  2007cited by this paper
• Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension

  2007cited by this paper
• Increased smooth muscle cell expression of caveolin‐1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertension

  2007cited by this paper
• Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease

  2007cited by this paper
• A cell model system to study regulation of phosphotidylinositol 3-kinase and protein kinase B activity by cytokines/growth factors produced by type I collagen stimulated immune cells from patients with systemic sclerosis.

  2007cited by this paper
• Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients.

  2007cited by this paper
• Autoantibody profile in the experimental model of scleroderma induced by type V human collagen

  2007cited by this paper
• Levels of circulating endothelial progenitor cells in systemic sclerosis.

  2007cited by this paper
• Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity.

  2007cited by this paper
• Characterisation of the immune response to type I collagen in scleroderma

  2006cited by this paper
• Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.

  2006cited by this paper
• Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study

  2006cited by this paper
• Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil

  2006cited by this paper

• Live imaging of vascular dynamics in mouse skin.

  2026cites this paper
• Probabilistic Clustering Using Multivariate Growth Mixture Model in Clinical Settings—A Scleroderma Example

  2026cites this paper
• Endothelin-1 as a Candidate Biomarker of Systemic Sclerosis: A GRADE-Assessed Systematic Review and Meta-Analysis With Meta-Regression

  2025cites this paper
• A review of recent studies on the pathogenesis of Systemic Sclerosis: focus on fibrosis pathways

  2025cites this paper
• How to Assess Pulmonary Circulation and Right Heart Chambers in Systemic Sclerosis Patients?

  2025cites this paper
• Separated or joint models of repeated multivariate data to estimate individuals’ disease trajectories with application to scleroderma

  2025cites this paper
• Upregulation of RAF and RalGDS gene expression by TGF-β in systemic sclerosis dermal fibroblasts: a controlled in vitro study

  2025cites this paper
• Necrotising Pancreatitis in a Patient with Crest Syndrome: A Rare Autoimmune Gastrointestinal Complication

  2025influential citation
• Refractory Digital Ulcers in Systemic Sclerosis Sine Scleroderma Associated With Antiphospholipid Syndrome: A Case-Based Review

  2025cites this paper
• Pathophysiology in Systemic Sclerosis: Current Insights and Future Perspectives

  2025cites this paper
• Platelet bound B cells and their role in SSc: Implications for disease subtypes and clinical outcomes.

  2025cites this paper
• Prediction of scleroderma renal crisis in patients of systemic sclerosis: insight from the CRDC cohort study.

  2025cites this paper
• Neutrophil extracellular traps induce pyroptosis of pulmonary microvascular endothelial cells by activating the NLRP3 inflammasome.

  2024cites this paper
• Peran Kepuasan Hidup dalam Pengelolaan Penyakit Systemic Sclerosis

  2024cites this paper
• Preclinical and Clinical Data on Current Therapeutic Options for Micro- and Macrovascular Abnormalities in Systemic Sclerosis

  2024cites this paper
• A Genome‐Wide Association Study Suggests New Susceptibility Loci for Primary Antiphospholipid Syndrome

  2024cites this paper
• ERG Regulates Lymphatic Vessel Specification Genes and Its Deficiency Impairs Wound Healing‐Associated Lymphangiogenesis

  2024cites this paper
• Single-cell transcriptomes and chromatin accessibility of endothelial cells unravel transcription factors associated with dysregulated angiogenesis in systemic sclerosis

  2024cites this paper
• An Innovative Approach of Examining Skin Changes Associated with Scleroderma from a Mechanical Perspective, Stiffness based Novel Analysis

  2024cites this paper
• Copeptin as a Biomarker of Microcirculation Alterations in Systemic Sclerosis

  2023cites this paper
• S1P/S1PR signaling pathway advancements in autoimmune diseases

  2023cites this paper
• Spectrum of Cerebrovascular Disease in Scleroderma: A Case Series and Systematic Review

  2023cites this paper
• Biomarkers in the Pathogenesis, Diagnosis, and Treatment of Systemic Sclerosis

  2023cites this paper
• Angiopoietin-like protein 2 mediates vasculopathy-driven fibrogenesis in a mouse model of systemic sclerosis

  2023cites this paper
• Stem cell-based therapy for systemic sclerosis

  2023cites this paper
• Associations of autoantibodies and clinical profile of the patients with systemic sclerosis

  2022cites this paper
• Microangiopathy in Inflammatory Diseases—Strategies in Surgery of the Lower Extremity

  2022cites this paper
• The role of endothelin and RAS/ERK signaling in immunopathogenesis-related fibrosis in patients with systemic sclerosis: an updated review with therapeutic implications

  2022cites this paper
• Pathogenetic Aspects of Systemic Sclerosis: A View Through the Prism of B Cells

  2022cites this paper
• LONG-TERM EVOLUTION OF BOSENTAN TREATMENT IN SYSTEMIC SCLEROSIS PATIENTS – THE EXPERIENCE OF A PRESCRIBING CENTRE FROM BUCHAREST, ROMANIA

  2022cites this paper
• Spontaneous innominate artery rupture in a patient with systemic sclerosis

  2022cites this paper
• The Microbiome in Systemic Sclerosis: Pathophysiology and Therapeutic Potential

  2022cites this paper
• Bosentan versus nifedipine in the treatment of vasculopathy in systemic sclerosis patients: A randomized control trial.

  2022influential citation
• The Prostacyclin Analogue Iloprost Modulates CXCL10 in Systemic Sclerosis

  2022cites this paper
• Predicting clinical events using Bayesian multivariate linear mixed models with application to scleroderma

  2021cites this paper
• Effect of vasodilator and immunosuppressive therapy on the endothelial dysfunction in patients with systemic sclerosis

  2021cites this paper
• Serotonin and Systemic sclerosis. An emerging player in pathogenesis.

  2021cites this paper
• Successful wound healing of refractory digital ulcer in patient with systemic sclerosis by Waon therapy.

  2021cites this paper
• Engineering Advanced In Vitro Models of Systemic Sclerosis for Drug Discovery and Development

  2021cites this paper
• Role of Alarmins in the Pathogenesis of Systemic Sclerosis

  2020cites this paper
• Systemic vascular distensibility relates to exercise capacity in connective tissue disease.

  2020cites this paper
• Epigenetics in Allergy and Autoimmunity

  2020cites this paper
• The Epigenetic Regulation of Scleroderma and Its Clinical Application.

  2020cites this paper
• High prevalence of salivary gland ultrasound abnormalities in systemic sclerosis.

  2020cites this paper
• Therapeutic molecular targets of SSc-ILD

  2020cites this paper
• Platelets in Skin Autoimmune Diseases

  2019cites this paper
• Title Selective deletion of PPAR / in fibroblasts causes dermalfibrosis by attenuated LRG 1 expression

  2019cites this paper
• Corneal Perforation after Nd: YAG Capsulotomy: A Case Report and Literature Review

  2019cites this paper
• Endothelium-mediated contributions to fibrosis.

  2019cites this paper
• N-terminal pro-brain natriuretic peptide in systemic sclerosis patients: correlation with nailfold capillaroscopy findings

  2019cites this paper
• ANGPTL3: a novel biomarker and promising therapeutic target

  2019cites this paper
• Exosomes in Systemic Sclerosis: Messengers Between Immune, Vascular and Fibrotic Components?

  2019cites this paper
• Nonthrombotic proliferative vasculopathy associated with antiphospholipid antibodies: A case report and literature review

  2019influential citation
• Oxidative/nitrative stress in the pathogenesis of systemic sclerosis: are antioxidants beneficial?

  2018cites this paper
• Epigenetics and pathogenesis of systemic sclerosis; the ins and outs.

  2018cites this paper
• Assessment of hand superficial oxygenation during ischemia/reperfusion in healthy subjects versus systemic sclerosis patients by 2D near infrared spectroscopic imaging

  2018cites this paper
• Editor’s Choice Optical Coherence Tomography Angiography of Normal Skin and Inflammatory Dermatologic Conditions

  2018cites this paper
• Selective deletion of PPARβ/δ in fibroblasts causes dermal fibrosis by attenuated LRG1 expression

  2018cites this paper
• Venous Thromboembolism in Systemic Sclerosis: Prevalence, Risk Factors, and Effect on Survival

  2018cites this paper
• Existing and novel biomarkers for precision medicine in systemic sclerosis

  2018cites this paper
• Effects of arterial blood on the venous blood vessel wall and differences in percentages of lymphocytes and neutrophils between arterial and venous blood

  2018cites this paper
• The clinical effects of l‐arginine and asymmetric dimethylarginine: implications for treatment in secondary Raynaud's phenomenon

  2018cites this paper
• The role of peroxisome proliferator-activated receptor β/δ in colorectal cancer

  2018cites this paper
• Vascular Mechanisms of Systemic Sclerosis

  2018cites this paper
• Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities

  2017influential citation
• Corrigendum: Agonistic Anti-PDGF Receptor Autoantibodies from Patients with Systemic Sclerosis Impact Human Pulmonary Artery Smooth Muscle Cells Function In Vitro

  2017cites this paper
• Agonistic Anti-PDGF Receptor Autoantibodies from Patients with Systemic Sclerosis Impact Human Pulmonary Artery Smooth Muscle Cells Function In Vitro

  2017cites this paper
• Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review

  2017cites this paper
• Structural and functional failure of fibrillin‑1 in human diseases (Review).

  2017cites this paper
• A novel iloprost administration method with portable syringe pump for the treatment of acral ulcers and Raynaud's phenomenon in systemic sclerosis patients. A pilot study (ILOPORTA).

  2017cites this paper
• Serum vascular endothelial growth factor (VEGF), soluble VEGF receptor-1 (sVEGFR-1) and sVEGFR-2 in systemic sclerosis patients: Relation to clinical manifestations and capillaroscopy findings

  2017cites this paper
• Endothelial cell-specific activation of transforming growth factor-β signaling in mice induces cutaneous, visceral, and microvascular fibrosis.

  2017cites this paper
• Geniposide inhibited endothelial-mesenchymal transition via the mTOR signaling pathway in a bleomycin-induced scleroderma mouse model.

  2017cites this paper
• Targeting interferons as a strategy for systemic sclerosis treatment.

  2017cites this paper
• Pulmonary Hypertension Associated With Scleroderma and Connective Tissue Disease: Potential Molecular and Cellular Targets

  2017cites this paper
• Platelet-derived sphingosine-1-phosphate and inflammation: from basic mechanisms to clinical implications

  2016cites this paper
• Histologic Characteristics of Systemic Vasculitis : A Comparative Postmortem Study of 33 Rheumatoid Arthritis and 11 Progressive Systemic Sclerosis Patients

  2016cites this paper
• Développement d’un nouveau modèle murin expérimental de sclérodermie

  2016cites this paper
• Intrinsic Deregulation of Vascular Smooth Muscle and Myofibroblast Differentiation in Mesenchymal Stromal Cells from Patients with Systemic Sclerosis

  2016cites this paper
• Clinical Phenotype of Endothelial Dysfunction in Romanian Scleroderma Patients.

  2016cites this paper
• Polymorphisms in STAT4 and IRF5 increase the risk of systemic sclerosis: a meta‐analysis

  2016cites this paper
• Echocardiographic assessment of cardiac andpulmonary manifestations in patientswith systemic sclerosis

  2015cites this paper
• Vasculopatía de grandes vasos en la esclerosis sistémica

  2015cites this paper
• The elevated expression of Th17-related cytokines and receptors is associated with skin lesion severity in early systemic sclerosis.

  2015cites this paper
• T and NK Cell Phenotypic Abnormalities in Systemic Sclerosis: a Cohort Study and a Comprehensive Literature Review

  2015cites this paper
• Two-Dimensional near Infrared Spectroscopic Imaging of the Hand to Assess Microvascular Abnormalities in Systemic Sclerosis: A Pilot Study

  2015cites this paper
• Epigenetics and Fibrosis: Lessons, Challenges, and Windows of Opportunity

  2015cites this paper
• Large vessels vasculopathy in systemic sclerosis

  2015cites this paper
• Systemic Vasculitis in Various Organs of 33 Rheumatoid Arthritis and 11 Progressive Systemic Sclerosis Patients - A Comparative Postmortem Study

  2015cites this paper
• ASSESSMENT OF INTRARENAL VASCULARIZATION IN DIFFUSE SYSTEMIC SCLEROSIS

  2015cites this paper
• Biomarker discovery in systemic sclerosis: state of the art

  2015cites this paper
• The Role of MicroRNAs in Autoimmune Diseases with Skin Involvement

  2015cites this paper
• The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist

  2015cites this paper
• Macro- and microvascular disease in systemic sclerosis.

  2015cites this paper
• The association between vibration and vascular injury in rheumatic diseases: A review of the literature

  2015cites this paper
• Clinical Phenotype of Endothelial Dysfunction in a Lot of Romanian Scleroderma Patients.

  2015cites this paper
• Pathogenesis of Systemic Sclerosis

  2015influential citation
• [Large vessels vasculopathy in systemic sclerosis].

  2015cites this paper
• Regulatory mechanisms of anthrax toxin receptor 1-dependent vascular and connective tissue homeostasis

  2015cites this paper
• Outcomes of sympathectomy and vascular bypass for digital ischaemia in connective tissue disorders

  2014cites this paper